Table 1.
Reported treatment choices for APDS patients. It should be noted that some individuals are included in more than one publication.
| APDS type | Coulter et al. (2017) (23) | Elkaim et al. (2016) (21) | Maccari et al. (2018) (24) | Tessarin et al. (2020) (82) | Jamee et al. (2020) (52) | Wang et al. (2021) (83) | ||
|---|---|---|---|---|---|---|---|---|
| APDS1 (n=53) |
APDS2 (n=36) |
APDS1/2 (n=68) |
APDS1 (n=45) |
APDS2 (n=23) |
APDS1 (n=8) |
APDS1/2 (n=240) | APDS1 (n=7) | |
| Antibiotics | 33 | 22 | 54 | 1 | ||||
| IgG | 46 | 32 | 44 | 28 | 16 | 6 | 151 | |
| Immunosuppr. | 16 | 3 | ||||||
| Rapamycin | 6 | 6 | 27 | 2 | 3 | |||
| Rituximab | 8 | 3 | 8 | |||||
| Steroids | 5 | 31 | 4 | |||||
| HSCT | 5 | 1 | 8 | 7 | 1 | 1 | 31 | |
| Splenectomy | 3 | 5 | 4 | 1 | 10 | |||
APDS, Activated PI3Kδ syndrome; HSCT, hematopoietic stem cell transplantation; IgG, Immunoglobulin G.